

## Correction: *Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study*

Naing A, Powderly JD, Nemunaitis JJ, *et al.* Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study. *J Immunother Cancer* 2022;10:e004223. doi: 10.1136/jitc-2021-004223

The last sentence of the section titled 'Group A (itacitinib plus epacadostat)' has been updated to 'Serious TEAEs considered by the investigator to be related to itacitinib and parsaclisib included aseptic meningitis (one in part 1a group B), one each of cardiomyopathy and pneumonitis in groups B-1 and B-2, and one each of lung infection and streptococcal bacteremia in group B-3, B-4, and B-5 population'.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See <https://creativecommons.org/licenses/by/4.0/>.

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.

*J Immunother Cancer* 2022;10:e004223corr1. doi:10.1136/jitc-2021-004223corr1

